Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial

Mann, Johannes; Schmieder, Roland; McQueen, Matthew; Dyal, Leanne; Schumacher, Helmut; Pogue, Janice; Wang, Xingyu; Maggioni, Aldo; Budaj, Andrzej; Chaithiraphan, Suphachai; Dickstein, Kenneth; Keltai, Matyas; Metsarinne, Kaj; Oto, Ali; Parkhomenko, Alexander; Piegas, Leopoldo; Svendsen, Tage; Teo, Koon; Yusuf, Salim

doi:10.1016/s0140-6736(08)61236-2

Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial

Copy For Citation

Mann J. F. E., Schmieder R. E., McQueen M., Dyal L., Schumacher H., Pogue J., ...More

LANCET, vol.372, no.9638, pp.547-553, 2008 (SCI-Expanded)

Publication Type: Article / Article
Volume: 372 Issue: 9638
Publication Date: 2008
Doi Number: 10.1016/s0140-6736(08)61236-2
Journal Name: LANCET
Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Page Numbers: pp.547-553
Hacettepe University Affiliated: Yes

Abstract

Background Angiotensin receptor blockers (ARB) and angiotensin converting enzyme (ACE) inhibitors are known to reduce proteinuria. Their combination might be more effective than either treatment alone, but long-term data for comparative changes in renal function are not available. We investigated the renal effects of ramipril (an ACE inhibitor), telmisartan (an ARB), and their combination in patients aged 55 years or older with established atherosclerotic vascular disease or with diabetes with end-organ damage.